Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00818779 · ClinicalTrials.gov registry record · Phase 4
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
A Phase 4 study, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
NCT00818779: Completed Phase 4 study, sponsored by Texas Tech University Health Sciences Center.
NCT00818779 is a Phase 4 study that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 38 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00818779, a Phase 4 study, has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
Study Summary
The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calcium channel blocker.
Primary Outcome
Plasminogen Activator Inhibitor 1 is a biomarker found in serum that indirectly assesses blood clotting activity. Lower PAI-1 levels are thought to be better than higher levels. The primary outcome is mean change from baseline and can include negative numbers as a result.
Interventions
- DRUG Amlodipine
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
What the finished NCT00818779 record still lists
NCT00818779 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Amlodipine is the first listed.
NCT00818779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00818779 about?
NCT00818779 is a clinical study titled "Direct Renin Inhibition Effects on Atherosclerotic Biomarkers". The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calc...
What is the current status of trial NCT00818779?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2008-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00818779?
The interventions under investigation include: Amlodipine (DRUG), Aliskiren (DRUG).
Who is sponsoring clinical trial NCT00818779?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00818779's enrollment target sits among peer trials
38 1476th of 2000 higher than 519 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia